Matutes E, Coelho E, Aguado M J, Morilla R, Crawford A, Owusu-Ankomah K, Catovsky D
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London.
J Clin Pathol. 1996 Feb;49(2):154-8. doi: 10.1136/jcp.49.2.154.
To investigate the reactivity with TIA-1 and TIA-2, two monoclonal antibodies that recognise, respectively, granular structures in T lymphocytes and the T cell receptor chain in cells from a variety of T cell disorders.
Cytoplasmic staining with TIA-1 and TIA-2 was carried out by the immunoalkaline phosphatase anti-alkaline phosphatase technique in 67 cases with a T cell disorder: 31 large granular lymphocyte (LGL) leukaemia, nine T-prolymphocytic leukaemia (T-PLL), five Sezary syndrome, four peripheral T cell lymphoma (PTCL), 13 T cell lymphocytosis, and five T-acute lymphoblastic leukaemia (T-ALL). All had over 75% abnormal T cells which were CD2+, CD3+, CD5+, CD7+, and negative with B cell markers.
TIA-1 was positive in 77% cases of LGL leukaemia and half of the PTCL and T-ALL, whereas it was negative in all Sezary syndrome and most T-PLL (8/9) and reactive T-lymphocytosis (10/13). In LGL leukaemia, TIA-1 was positive irrespective of the membrane phenotype, whether CD8+, CD4- or CD4+, CD8-, and was more often positive in cases where cells were CD16+, CD56+, or CD57+. TIA-2 was positive in 60% of cases encompassing all diagnostic types of T cell disorder. There was no correlation between TIA-2 expression and that of other T cell markers, activation antigens, and natural killer markers.
The pattern of TIA-1 expression in T cell malignancies may help in the differential diagnosis among LGL leukaemia (high expression), T cell lymphocytosis and other T cell diseases (low expression). As TIA-2 is expressed in over 95% mature T lymphocytes and thymic cells, its assessment may be useful to demonstrate aberrant phenotypes which can be exploited for detecting minimal residual disease.
研究TIA - 1和TIA - 2的反应性，这两种单克隆抗体分别识别T淋巴细胞中的颗粒结构以及多种T细胞疾病细胞中的T细胞受体链。
采用免疫碱性磷酸酶抗碱性磷酸酶技术，对67例T细胞疾病患者进行TIA - 1和TIA - 2的细胞质染色，这些患者包括31例大颗粒淋巴细胞（LGL）白血病、9例T - 前淋巴细胞白血病（T - PLL）、5例Sezary综合征、4例外周T细胞淋巴瘤（PTCL）、13例T细胞淋巴细胞增多症以及5例T - 急性淋巴细胞白血病（T - ALL）。所有患者异常T细胞均超过75%，这些细胞CD2 +、CD3 +、CD5 +、CD7 +，且B细胞标志物呈阴性。
TIA - 1在77%的LGL白血病病例以及一半的PTCL和T - ALL病例中呈阳性，而在所有Sezary综合征以及大多数T - PLL（8/9）和反应性T淋巴细胞增多症（10/13）病例中呈阴性。在LGL白血病中，无论膜表型是CD8 +、CD4 - 还是CD4 +、CD8 -，TIA - 1均呈阳性，且在细胞为CD16 +、CD56 +或CD57 +的病例中更常呈阳性。TIA - 2在涵盖所有诊断类型的T细胞疾病的60%病例中呈阳性。TIA - 2表达与其他T细胞标志物、活化抗原和自然杀伤标志物的表达之间无相关性。
T细胞恶性肿瘤中TIA - 1的表达模式可能有助于LGL白血病（高表达）、T细胞淋巴细胞增多症和其他T细胞疾病（低表达）之间的鉴别诊断。由于TIA - 2在超过95%的成熟T淋巴细胞和胸腺细胞中表达，其评估可能有助于显示异常表型，可用于检测微小残留病。
